Cyient DLM shares rallied as much as 6% to ₹360.20 on April 21, 2026, following the company's March quarter (Q4 FY26) results announcement. According to HomeStocksNews, the electronic manufacturing services firm's stock performance reflected positive investor sentiment despite the mixed financial results, with the market focusing on forward-looking indicators over current quarterly performance.
The electronic manufacturing services firm reported a 27.7% decline in consolidated net profit at ₹22.4 crore for the March quarter of FY26, compared to ₹31 crore in the year-ago period. As reported by HomeStocksNews, revenue from operations came in 13.8% lower at ₹369 crore in Q4 FY26, compared to ₹428 crore logged a year ago. EBITDA also slid 25% to ₹42.9 crore, with EBITDA margins narrowing to 11.6% from 13.4% year-on-year. However, on a quarter-on-quarter basis, the company showed strong recovery with profit rising 99.8% and revenue increasing 21.7%.
Despite the quarterly profit decline, Cyient DLM achieved its highest order book in a decade at ₹2,416.6 crore, with a book-to-bill ratio consistently above one across all quarters. As reported by HomeStocksNews, this substantial backlog signals strong demand and future revenue growth potential, with the company's closing order book reaching the decade high. The strong backlog, coupled with positive outlook for India's EMS and Aerospace & Defence sectors, appears to outweigh the current quarterly performance challenges.
The company's defense segment saw a significant 68% year-on-year decline in Q4 FY26, largely due to the completion of major aerospace and defense contracts. However, aerospace remains the dominant revenue segment, with Printed Circuit Board Assemblies (PCBA) making up 48% of revenue and box build revenue growing 17% year-on-year. International markets, especially from aerospace, medical, and industrial clients, are driving growth, with India contributing a smaller 8%. The company plans to diversify into medical and industrial sectors alongside aerospace to achieve more consistent order inflows.
Analysts hold a cautiously optimistic view, with consensus suggesting the "worst appears to be behind" for Cyient DLM and growth is expected to resume from Q4 FY26. According to HomeStocksNews, the average analyst target price is ₹469.67, representing a potential upside of over 30% from the current stock price, with most recommendations leaning towards 'Accumulate' or 'Buy'. The company's strategy includes expanding its manufacturing footprint, possibly via acquisitions in North America and EMEA, and diversifying into medical and industrial sectors. Successfully executing these plans is key for Cyient DLM to capitalize on the strong growth potential within the expanding Indian EMS and Aerospace & Defence industries.
